Exchange: NASDAQ·Updated 07:35 PM EDT
News
all
press releases
All You Need to Know About Rein Therapeutics Inc. (RNTX) Rating Upgrade to Buy
Rein Therapeutics Inc. (RNTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
Rein Therapeutics Inc. (NASDAQ:RNTX) Short Interest Down 51.4% in April
Rein Therapeutics Inc. (NASDAQ:RNTX - Get Free Report) was the target of a significant drop in short interest in the month of April. As of April 15th, there was short interest totaling 236,711...
MarketBeat

Advertisement|Remove ads.